Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by Richmondon Oct 06, 2021 5:00pm
162 Views
Post# 33977471

RE:Researched- XRX is after UNMET Medical Needs

RE:Researched- XRX is after UNMET Medical NeedsThat's all good to know but the HUGE SWINGS UP AND DOWN are becoming a nightmare. From $7.90 yesterday to $6.36 today is looking like an error on the part of the Management!!!!. The ROLLBACK was done with a big divider of 11.74 to one and done too early.. 5:1 would have been suitable CLOSER towards the LISTING of NASDAQ. . I, with of us had said that ROLLBACKs have never worked. What's the point of consolidating at 11.74 to $10.00, when it's at $6.36 today and was in $5's last week. Created profit taking scenario for the insiders!!! or day traders!!!!. Not Good decision here at all....Till we hit NASDAQ LISTING, thus volatility will remain...shiiittts!!!!
SpaceLabs wrote: This will FLY out of the Gates on Nasdaq.
It has a GREAT Team and the Drugs are all working , phase 3 will be a quick walk thru. Been proven in phase II.

This is the DRUG for all Kidney related diseases and  the prevention, especially for those over 60yrs.,,,,millions are candidates waiting for a Miracle Drug.


<< Previous
Bullboard Posts
Next >>